Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.
FineAJSorbelloAKortepeterCet al. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis2013; 57: 849–852.
2.
ValenzuelaRMPulaJHGarwackiDet al. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci2014; 340: 109–111.
3.
PolmanCHO’ConnorPWHavrdovaEet al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
4.
RudickRAStuartWHCalabresiPAet al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
5.
BörnkeCPrzuntekHPostertTet al. Atypical multiple sclerosis presenting as chronic-progressive encephalomyelitis with polyneuritis and recurrent aseptic meningitis. J Neurol1999; 246: 136–139.
6.
AbsintaMVuoloLRaoAet al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85: 18–28.
7.
VillaniVProsperiniLDe GiglioLet al. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis. Headache2012; 52: 1130–1135.
8.
StuveOCravensPDSinghMPet al. High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: Role of intrathecal leukocytes. Arch Neurol2007; 64: 1055–1056.
9.
NaranjoCABustoUSellersEMet al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
10.
BharathVEckertKKangMet al. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: A retrospective review at a single tertiary care center. Transfusion2015; 55: 2597–2605.
11.
MantheyCLohseAWPaceA.Case report of aseptic meningitis in a patient with Crohn’s disease under infliximab therapy. Inflamm Bowel Dis2011; 17: e10.
12.
JazeronALallierJCRihnBet al. Aseptic meningitis possibly induced by adalimumab. Joint Bone Spine2010; 77: 618–619.
VoskensCJGoldingerSMLoquaiCet al. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE2013; 8: e.53745.
